Takeda Pharmaceutical Company

Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer

Retrieved on: 
Monday, August 7, 2023
Takeda Pharmaceutical Company, Business development, Partnership, Novartis Institute for Tropical Diseases, University, Gastroenterology, Doctor of Philosophy, Takeda, Head, Physician, Roche, University of California, Research, Biomedical Research, Strategic planning, Rutgers University, Gastrointestinal tract, Novartis, Patient, Columbia University Vagelos College of Physicians and Surgeons, CBO, M.A, Therapy, Neurology, Pharmaceutical industry, Neuroscience, Voyager, Ophthalmology, Surgeon

CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Beth Shafer, Ph.D., M.A., M.Phil., as Chief Business Officer (CBO).

Key Points: 
  • CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Beth Shafer, Ph.D., M.A., M.Phil., as Chief Business Officer (CBO).
  • Shafer is a seasoned healthcare executive with more than 15 years of experience in corporate and business development at prominent biopharmaceutical companies, as well as deep knowledge in neurology.
  • She previously held multiple corporate and business development roles of increasing responsibility during her tenures at Takeda, Novartis and Roche.
  • “I look forward to helping the team leverage business development and strategy to achieve its mission of advancing life-changing genetic medicines for neurological diseases.”

Dallas DEI Tech Firm Partners with Dallas Regional Chamber to Educate and Equip Senior Leaders to Impact DEI in Difficult Times

Retrieved on: 
Thursday, August 3, 2023
DRC, Partnership, Dallas Regional Chamber, Face, Dallas Holocaust and Human Rights Museum, DEIB, KJE, Organization, Inclusion, DEI, Climate, Growth, Community engagement, WebPT, EVOLVE, Takeda Pharmaceutical Company, Management

PLANO, Texas, Aug. 3, 2023 /PRNewswire/ -- KEIRUS BY KJE is pleased to announce the annual KEIRUS EVOLVE Experience will be happening this year on September 12, 2023. Last year KEIRUS EVOLVE was a virtual conference for KEIRUS BY KJE clients who influence the DEIB focus of their organizations. In September it will be an in-person event for senior leaders and practitioners who are responsible for DEIB and workplace culture initiatives.

Key Points: 
  • In September it will be an in-person event for senior leaders and practitioners who are responsible for DEIB and workplace culture initiatives.
  • KEIRUS EVOLVE 2023 will be presented in partnership with the Dallas Regional Chamber.
  • The KEIRUS EVOLVE experience will be an opportunity for senior leaders to connect with peers and gain actionable insights.
  • KEIRUS EVOLVE, hosted in partnership with the Dallas Regional Chamber, will be held at the Dallas Holocaust and Human Rights Museum in Downtown Dallas.

Sustainability Takes Center Stage at the 2023 PODD Drug Delivery Conference

Retrieved on: 
Thursday, August 3, 2023
Teva Pharmaceuticals, Computational biology, GSK, Amgen, Gilead Sciences, Senior, Regeneron Pharmaceuticals, Roche, Gene editing, Copley Place, Bristol Myers Squibb, Medicine, AstraZeneca, CNS, PNS, Beam Therapeutics, Development, Digital technology, Eli Lilly and Company, Novartis, Patient, AbbVie, Novo Nordisk, Sanofi, Ionis Pharmaceuticals, Johnson & Johnson, Therapy, Conference, Takeda Pharmaceutical Company, Medical device, Clothing, Pharmaceutical industry, Teva, Genentech, Device, Pfizer

NEW YORK, Aug. 3, 2023 /PRNewswire-PRWeb/ -- The Conference Forum announced that the 13th annual PODD: Partnership Opportunities in Drug Delivery conference will feature sustainability as a main topic addressed throughout the agenda, October 16-17 at the Westin Copley Place, in Boston, MA.

Key Points: 
  • The Conference Forum announced that the 13th annual PODD Drug Delivery Conference will address implementing sustainability in device development.
  • NEW YORK, Aug. 3, 2023 /PRNewswire-PRWeb/ -- The Conference Forum announced that the 13th annual PODD: Partnership Opportunities in Drug Delivery conference will feature sustainability as a main topic addressed throughout the agenda, October 16-17 at the Westin Copley Place, in Boston, MA.
  • The PODD 2023 conference featured sustainability sessions include:
    Dr Marianne Ølholm, Senior Vice President, Devices and Delivery Solutions, Novo Nordisk, will join the PODD Conference as the Sustainability Keynote.
  • With pharmaceutical companies committing to reduce emissions and decarbonize, the PODD conference will highlight cross-industry perspectives on integrating sustainability in the development of drug delivery technologies.

Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

Retrieved on: 
Wednesday, August 2, 2023
Drug development, University, Therapy, Leo Pharma, Takeda, Horizon Therapeutics, Abbott Laboratories, CMC, TAP Pharmaceuticals, Geographic atrophy, Marquette University, Acquisition, Patient, University of Illinois Urbana-Champaign, Regulatory affairs, Market production, Rare, Orthostatic hypertension, FDA, Autoimmunity, Takeda Pharmaceutical Company, Inflammation, Champaign–Urbana metropolitan area, Pharmaceutical industry, Pharmacovigilance, Akari

NEW YORK and LONDON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of Beth-Anne Lang, as Senior Vice President, Regulatory Affairs.

Key Points: 
  • NEW YORK and LONDON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of Beth-Anne Lang, as Senior Vice President, Regulatory Affairs.
  • Ms. Lang has more than 20 years of experience in regulatory strategy, regulatory affairs, and drug development.
  • Previously, she was Vice President, Regulatory Affairs for Horizon Therapeutics, leading a global regulatory organization and directing regulatory strategy ahead of the acquisition of Viela Bio and subsequent integration.
  • She held roles of increasing scope and responsibility at Takeda Pharmaceuticals including Vice President, Global Regulatory Affairs, Marketed Products.

Armis and Security Risk Advisors Announce Strategic Partnership

Retrieved on: 
Wednesday, August 2, 2023
Data Management, Security, Technology, Software, Networks, Internet, SRA, Partnership, Takeda, Pulse, Organization, Patient, CPS, Risk assessment, Business, APEX, Takeda Pharmaceutical Company, Risk management, United States Army Command, Control, Communication, Computers, Cyber, Intelligence, Surveillance and Reconnaissance Center

Armis , the leading asset visibility and security company, today announced a strategic partnership with international cybersecurity consulting firm, Security Risk Advisors (SRA).

Key Points: 
  • Armis , the leading asset visibility and security company, today announced a strategic partnership with international cybersecurity consulting firm, Security Risk Advisors (SRA).
  • Their platform allows us to be more proactive about CPS/OT security measures and have a better reactive grasp on security events and incidents.
  • We’re narrowing the gap between Armis’ industry-leading technology and organizations who need to grow their CPS/OT security capabilities.”
    SRA is a member of the Armis Partner Experience (APEX) program .
  • Learn more about Armis’ OT cybersecurity solutions and how the company is helping customers secure operational technology here: https://www.armis.com/solutions/ot-device-security/
    To request an ICS Risk Assessment from Armis, please visit: https://www.armis.com/ics-security-risk-assessment/
    To learn more about SRA’s Cyber Physical Systems security services, please visit: https://sra.io/cpss

Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 1, 2023
General Health, Public Relations, Investor Relations, Health, Communications, Oncology, Table, Prostate cancer, Takeda Pharmaceutical Company, Clinical trial, EXEL, Cancer, GAAP, Research, Patient, Ipilimumab, Collaboration, Survival analysis, Total, Nivolumab, Renal cell carcinoma, Pharmaceutical industry, Reinsurance, Insurance, Exelixis

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.
  • “In the second quarter of 2023, the Exelixis team continued to make steady progress both on our commercial business and our rapidly advancing pipeline,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis.
  • Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors.
  • Exelixis is maintaining the previously provided financial guidance for fiscal year 2023:

uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Tuesday, August 1, 2023
Senior, Takeda, Abbott Laboratories, CSL, American Society of Gene and Cell Therapy, Associate, Research and development, Development, Patient, Cell, Toxicology, Fabry disease, ALS, Gene, General counsel, Research, Forma, SOD1, Corporation, CSF, Wells Fargo, IND, Unified, Conference, Safety, GLP, Abstract, Natural history, CSL Behring, Cancer, AAV, Primate, Therapy, Takeda Pharmaceutical Company, Commercialization, AFL, Clinical trial, Sale, Novartis, Takeda Oncology, Novo Nordisk, Immunosuppression, Society, Pharmaceutical industry, Cryptocurrency, EU, Pfizer

and AMSTERDAM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2023 and highlighted recent progress across its business.

Key Points: 
  • and AMSTERDAM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2023 and highlighted recent progress across its business.
  • The Company continues to make progress enrolling the second, high-dose cohort of nine patients and expects to complete enrollment in the third quarter of 2023.
  • The Company expects to initiate a Phase I/II clinical study of AMT-162 in the second half of 2023.
  • The Company expects cash, cash equivalents and investment securities will fund operations into the second quarter of 2026.

Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, July 27, 2023
Tufts University, UNITY, Endocrinology, Biotechnology, Drug development, University, Takeda, Eli Lilly and Company, Head, Unity Biotechnology, Science, Eli Lilly, Lilly, Patient, Collection, Metabolism, Takeda Pharmaceutical Company, Pharmaceutical industry

BRISBANE, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the appointment of Jamie Dananberg, M.D., as chief medical officer.

Key Points: 
  • BRISBANE, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the appointment of Jamie Dananberg, M.D., as chief medical officer.
  • “We are delighted to join forces with Jamie during this exciting time for Annexon.
  • Most recently, he served as the chief medical officer for UNITY Biotechnology, where as one of its earliest employees, he built the medical and broader development organization.
  • Before joining Lilly, he practiced medicine in endocrinology and metabolism and ran a basic science laboratory at the University of Michigan.

KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer

Retrieved on: 
Tuesday, July 25, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, BS, Hereditary angioedema, Marketing, Carroll School of Management, Praxis, NDA, Multimedia, CNS, HAE, Shire (pharmaceutical company), Boston College, KALV, Disease, Takeda Pharmaceutical Company, Pharmaceutical industry, Takeda

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today the appointment of Nicole Sweeny as Chief Commercial Officer.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today the appointment of Nicole Sweeny as Chief Commercial Officer.
  • View the full release here: https://www.businesswire.com/news/home/20230725517894/en/
    KalVista Chief Commercial Officer Nicole Sweeny (Photo: Business Wire)
    “As KalVista prepares for our evolution into a commercial organization, we continue to strategically add individuals with deep experience in hereditary angioedema (HAE) product launches and global commercialization,” said Andrew Crockett, Chief Executive Officer of KalVista.
  • Most recently, Ms. Sweeny served as Chief Commercial Officer at Praxis Precision Medicines, where she led commercial strategy and built capabilities to support global launches for both common and rare CNS conditions.
  • Ms. Sweeny received a BS in Marketing from the Carroll School of Management at Boston College.

Oncology Care Partners Names Dr. Chevon Rariy Chief Health Officer

Retrieved on: 
Thursday, July 13, 2023
Oncology Care Model, Endocrinology, University, Internal medicine, Amazon (company), University of Pittsburgh Medical Center, Quality of life, Research, SVP-24, Government, Harvard Medical School, Cancer Treatment Centers of America, Amazon, Cancer, City, OCP, Publication, Brigham, Digital health, MD, Patient, Op-ed, Machine learning, Artificial intelligence, Hospital, Health, SVP, Brigham and Women's Hospital, Takeda Pharmaceutical Company, Nursing, Medical imaging

NASHVILLE, Tenn., July 13, 2023 /PRNewswire/ -- Oncology Care Partners (OCP), an oncology provider built solely to provide value-based care, today announces the appointment of Chevon Rariy, MD as Chief Health Officer—further elevating its telehealth and digital health capabilities to enhance both patient and provider experience.

Key Points: 
  • NASHVILLE, Tenn., July 13, 2023 /PRNewswire/ -- Oncology Care Partners (OCP), an oncology provider built solely to provide value-based care, today announces the appointment of Chevon Rariy, MD as Chief Health Officer—further elevating its telehealth and digital health capabilities to enhance both patient and provider experience.
  • "I am thrilled to join the dynamic team at OCP, where we are revolutionizing oncology care through a patient-centric value-based approach," said Chevon Rariy, MD.
  • "We are beyond excited to have Dr. Rariy join our senior leadership team," said Erich Mounce, CEO, Oncology Care Partners.
  • With its first two practices across three locations in Phoenix and Miami, Oncology Care Partners is committed to advancing value-based care in oncology nationwide by bringing high-touch, whole-person care that enhances the patient experience across its medical oncology practices.